Experienced in Micrognathia

Hiroyuki Shimada

Obu, JP 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Micrognathia
Obu, JP 
OverviewLocationsClinical Research

Overview

Hiroyuki Shimada practices in Obu, Japan. Mr. Shimada is rated as an Experienced expert by MediFind in the treatment of Micrognathia. His top areas of expertise are Dementia, Endophthalmitis, Muscle Atrophy, Vitrectomy, and Cataract Removal.

His clinical research consists of co-authoring 527 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Obu, Japan
Other Locations
Japan
Toyota, Japan
Saitama, 3300854, Japan
Okazaki, Japan
Tokyo, Japan
Sumiyoshi, Japan
Nagoya, Japan
Matsumoto, 3908621, Japan
Osaka, Japan
Chiyoda, 1018309, Japan
Morioka, Japan
Asahi, Japan
Chiba, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Dominantly Inherited Alzheimer Network (DIAN)
Dominantly Inherited Alzheimer Network (DIAN)
Enrollment Status: Recruiting
Publish Date: October 28, 2025
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: November 12, 2025
Intervention Type: Drug
Study Drugs: E2814, Lecanemab
Study Phase: Phase 2/Phase 3
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: November 12, 2025
Intervention Type: Drug
Study Drugs: Gantenerumab, Solanezumab
Study Phase: Phase 2/Phase 3
View 2 Less Clinical Trial

527 Total Publications

The impact of involvement in social activities on dementia onset: The role of willingness.
The impact of involvement in social activities on dementia onset: The role of willingness.
Journal: Journal of Alzheimer's disease : JAD
Published: December 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Shimada's expertise for a condition
ConditionClose
    View All 30 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile